What happened with AGMB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
AgomAb Therapeutics NV is testing potential treatments for diseases involving fibrosis, or tissue scarring, and inflammation. Most of its development resources have gone into ontunisertib and AGMB-447. It holds exclusive worldwide development and commercialization rights to its candidates, but none is approved for sale.
The company currently funds its work with capital raised from investors, supplemented by government grants and research incentives, rather than customer revenue. Its intended commercial business is to sell medicines after successful trials and regulatory approval. Patients’ access would depend heavily on government programs and private insurers covering treatment costs. AgomAb also relies on outside manufacturers for drug supply and needs further capital to bring its candidates through development and into commercial use.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Agomab’s prospects hinge on clinical success in fibrostenosing Crohn’s disease and pulmonary fibrosis, with RedX Pharma, Enveda and Boehringer Ingelheim important competitive benchmarks missing from this list.
Palisade Bio’s locally acting oral PALI-2108 competes with Agomab’s ontunisertib for fibrostenosing Crohn’s disease; both companies are developing medicines rather than selling approved products. Watch whether PALI-2108’s lower-intestine activation delivers its intended tolerability advantage.
Avalyn Pharma’s inhaled pulmonary-fibrosis candidates compete with Agomab’s inhaled AGMB-447 for patients with idiopathic pulmonary fibrosis (IPF), and neither company has approved products to sell. Avalyn’s AP02, in Phase 2 development for IPF, is the trial program to watch for this overlap.
United Therapeutics is seeking IPF approval for inhaled Tyvaso after positive Phase 3 trials, directly challenging the treatment opportunity for Agomab’s AGMB-447. It already sells Tyvaso for pulmonary hypertension; watch its planned FDA filing for IPF, rather than treating existing Tyvaso sales as IPF revenue.
Contineum Therapeutics’ systemic IPF candidate competes with Agomab’s inhaled AGMB-447 within a broader pipeline for neurological, immune and inflammatory diseases. Its IPF development news is the relevant comparison—not payments from J&J for rights to develop, manufacture and sell the separate PIPE-307 program.
MannKind’s inhaled IPF candidates compete with Agomab’s AGMB-447, while its existing business already makes inhaled medicines for commercial sale. MannKind manufactures and supplies Tyvaso DPI to United Therapeutics and earns supply revenue and royalties on net sales, giving it an established pulmonary-delivery business alongside its competing pipeline.
Bristol Myers Squibb challenges Agomab on two fronts: systemic IPF treatments and drugs that inhibit the TGF-beta pathway to address fibrosis. The company develops, manufactures and sells medicines for serious diseases; its fibrosis-program progress is more relevant to Agomab than its broad medicine sales.
Galectin Therapeutics’ liver-fibrosis and cirrhosis development competes for the same treatment opportunity as Agomab’s AGMB-101, with both companies still developing medicines rather than selling approved products. Watch development of Galectin’s lead candidate belapectin, designed to bind to and inhibit galectin-3.
Inventiva’s liver-fibrosis development overlaps with Agomab’s AGMB-101 cirrhosis opportunity, but Inventiva now concentrates on oral lanifibranor for MASH. Lanifibranor is its only candidate in development, so its progress—not a broader cirrhosis pipeline—is the comparison to watch.
Madrigal Pharmaceuticals’ liver-fibrosis or cirrhosis development overlaps with Agomab’s AGMB-101 opportunity, but Madrigal already has a commercial business built on Rezdiffra, its only approved product. Watch its fibrosis and cirrhosis development separately from Rezdiffra’s U.S. product sales; Agomab reports no approved treatment for cirrhosis.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb’s fibrosis-program update shows how far another company has advanced in targeting the TGF-beta pathway Agomab is also pursuing.
Look for whether Bristol Myers Squibb advances its fibrosis programs and whether any reported progress involves TGF-beta inhibition. Continued progress with meaningful clinical evidence would make the competition around this anti-fibrosis pathway more concrete for AgomAb; a stall or lack of progress would leave one fewer rival advancing along it, but would not show that AgomAb’s drug works.
United Therapeutics Corp earningsUTHR
United Therapeutics’ report can show how close inhaled Tyvaso is to entering the IPF treatment market that AGMB-447 may one day compete in.
Watch United Therapeutics’ regulatory update on Tyvaso for idiopathic pulmonary fibrosis (IPF), including whether it advances a planned FDA filing. Progress toward filing would put a potential inhaled competitor closer to the market for AGMB-447; delay or a setback would make that challenge less immediate. Existing Tyvaso sales for pulmonary hypertension are not IPF sales.
Palisade Bio, Inc. earningsPALI
Palisade Bio’s PALI-2108 update shows whether its oral treatment for fibrostenosing Crohn’s disease is becoming a competitor to Agomab’s ontunisertib.
Look for PALI-2108’s development progress and whether Palisade Bio reports evidence that its lower-intestine activation delivers the intended tolerability advantage. Solid clinical progress with that advantage supported would make PALI-2108 a more credible rival to AgomAb’s ontunisertib for the same disease; limited progress or no demonstrated advantage would weaken that rival, but would not establish that ontunisertib works.
Avalyn Pharma Inc. earningsAVLN
Avalyn Pharma’s AP02 is an inhaled IPF candidate, and its progress shows the development competition facing AGMB-447.
Watch AP02’s Phase 2 progress and the clinical evidence Avalyn Pharma reports. Clear progress would give Agomab’s AGMB-447 another inhaled IPF rival at a similar development stage, pursuing the same patient group; slow progress or a setback would leave that competitor further behind, but would not establish AGMB-447’s effectiveness.
Galectin Therapeutics Inc. earningsGALT
Galectin Therapeutics’ belapectin update shows how far another company has advanced in the liver-fibrosis and cirrhosis treatment opportunity that overlaps with Agomab.
Look for belapectin’s development progress; the candidate is designed to bind to and inhibit galectin-3. Convincing clinical progress would make Galectin Therapeutics a more credible development rival to Agomab’s AGMB-101 in liver fibrosis and cirrhosis; stalled progress or weak evidence would leave its candidate less advanced, but would not show that AGMB-101 works.
